- Blockade of the IL-11 pathway with LASN01 offers a potential new therapeutic option for thyroid eye disease
SAN DIEGO, CA, USA I October 02, 2023 ILassen Therapeutics, a clinical stage biotechnology company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R; LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), and interleukin-18 binding protein (IL-18BP; LASN500), as a potential treatment for cancer, presented new preclinical data on LASN01, for treatment of TED, at the American Thyroid Association (ATA) Annual Meeting held in Washington DC, September 27 through October 1, 2023.
“We continue our work in demonstrating the potential benefit of LASN01 in orbital fibroblasts, the relevant cell type for thyroid eye disease,” said Maria Fardis, PhD, MBA, CEO at Lassen. “In preclinical studies, LASN01 led to the suppression of cell proliferation and hyaluronan secretion from primary TED orbital fibroblasts, in addition to demonstrating anti-fibrotic activity. These results indicate that LASN01 has the potential to be a new therapeutic agent for the treatment of TED.”
A poster entitled “LASN01, a high affinity anti-interleukin-11 receptor antibody, blocks pathological mechanisms of thyroid eye disease linked to clinical efficacy” described how LASN01 inhibits hyaluronic acid (HA) release, proliferation, and procollagen production in response to IL-11, the combination of IL-11 and IGF-1, or TGFβ in orbital fibroblasts (OF) from TED patients following orbital decompression surgery. The effects of LASN01 on HA release and OF proliferation were comparable to the approved anti-IGF-1R antibody, teprotumumab, indicating that LASN01 should be further investigated as a potential new therapeutic agent for the treatment of TED.
About Lassen Therapeutics
Lassen Therapeutics is a clinical-stage biotech developing first-in-class antibodies as potential treatments for fibrosis, thyroid eye disease, and oncology. The company’s lead candidate, LASN01, is a first-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11 is a central mediator of fibrosis and blocking its activity has the potential to offer novel modality for treatment of TED and other fibrotic diseases. For more information, please visit www.lassentherapeutics.com and follow us on LinkedIn.
SOURCE: Lassen Therapeutics
Post Views: 222
- Blockade of the IL-11 pathway with LASN01 offers a potential new therapeutic option for thyroid eye disease
SAN DIEGO, CA, USA I October 02, 2023 ILassen Therapeutics, a clinical stage biotechnology company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R; LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), and interleukin-18 binding protein (IL-18BP; LASN500), as a potential treatment for cancer, presented new preclinical data on LASN01, for treatment of TED, at the American Thyroid Association (ATA) Annual Meeting held in Washington DC, September 27 through October 1, 2023.
“We continue our work in demonstrating the potential benefit of LASN01 in orbital fibroblasts, the relevant cell type for thyroid eye disease,” said Maria Fardis, PhD, MBA, CEO at Lassen. “In preclinical studies, LASN01 led to the suppression of cell proliferation and hyaluronan secretion from primary TED orbital fibroblasts, in addition to demonstrating anti-fibrotic activity. These results indicate that LASN01 has the potential to be a new therapeutic agent for the treatment of TED.”
A poster entitled “LASN01, a high affinity anti-interleukin-11 receptor antibody, blocks pathological mechanisms of thyroid eye disease linked to clinical efficacy” described how LASN01 inhibits hyaluronic acid (HA) release, proliferation, and procollagen production in response to IL-11, the combination of IL-11 and IGF-1, or TGFβ in orbital fibroblasts (OF) from TED patients following orbital decompression surgery. The effects of LASN01 on HA release and OF proliferation were comparable to the approved anti-IGF-1R antibody, teprotumumab, indicating that LASN01 should be further investigated as a potential new therapeutic agent for the treatment of TED.
About Lassen Therapeutics
Lassen Therapeutics is a clinical-stage biotech developing first-in-class antibodies as potential treatments for fibrosis, thyroid eye disease, and oncology. The company’s lead candidate, LASN01, is a first-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11 is a central mediator of fibrosis and blocking its activity has the potential to offer novel modality for treatment of TED and other fibrotic diseases. For more information, please visit www.lassentherapeutics.com and follow us on LinkedIn.
SOURCE: Lassen Therapeutics
Post Views: 222
